A Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab plus Investigational Agents in Combination with Etoposide and Cisplatin or Carboplatin for the First-Line Treatment of Participants with Extensive-Stage Small Cell Lung Cancer (KEYNOTE-B99)
Latest Information Update: 19 Apr 2024
At a glance
- Drugs Boserolimab (Primary) ; Carboplatin (Primary) ; Cisplatin (Primary) ; Etoposide (Primary) ; Lenvatinib (Primary) ; MK-4830 (Primary) ; Pembrolizumab (Primary)
- Indications Small cell lung cancer
- Focus Pharmacogenomic; Therapeutic Use
- Acronyms KEYNOTE-B99
- Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.
- 06 Mar 2023 Status changed from recruiting to active, no longer recruiting.
- 21 Jul 2021 Status changed from not yet recruiting to recruiting.
- 10 Jun 2021 New trial record